- Home
- Publications
- Publication Search
- Publication Details
Title
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 7, Pages 2243
Publisher
MDPI AG
Online
2020-07-22
DOI
10.3390/jcm9072243
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
- (2020) Dario Giugliano et al. Cardiovascular Diabetology
- Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
- (2020) David Z. I. Cherney et al. DIABETOLOGIA
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors
- (2020) Milton Packer JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
- (2020) Meg J. Jardine et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
- (2020) Anne C. Hesp et al. KIDNEY INTERNATIONAL
- The tubular hypothesis of nephron filtration and diabetic kidney disease
- (2020) Volker Vallon et al. Nature Reviews Nephrology
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate
- (2020) Yao Qiao et al. JAMA Internal Medicine
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia
- (2019) Jie Zhang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics
- (2019) Roberto Minutolo et al. JOURNAL OF NEPHROLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
- (2019) Kitty J. Jager et al. KIDNEY INTERNATIONAL
- Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
- (2019) Felice Nappi et al. Medicina-Lithuania
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c
- (2019) Christopher P. Cannon et al. CIRCULATION
- Preserving Kidney Function Instead of Replacing It
- (2019) Alan S. Kliger et al. Clinical Journal of the American Society of Nephrology
- The new biology of diabetic kidney disease - mechanisms and therapeutic implications
- (2019) Yuliya Lytvyn et al. ENDOCRINE REVIEWS
- Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population
- (2019) James B Wetmore et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Renal physiology of glucose handling and therapeutic implications
- (2019) David Z Cherney et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- SGLT-2 Inhibitors and Cardiovascular Risk
- (2018) Matthew A. Cavender et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe
- (2018) Katharina Brück et al. KIDNEY INTERNATIONAL
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study
- (2018) Chintan V. Dave et al. DIABETES OBESITY & METABOLISM
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
- (2018) K.I. Birkeland et al. DIABETES OBESITY & METABOLISM
- Effects of Intensive BP Control in CKD
- (2017) Alfred K. Cheung et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Low renal replacement therapy incidence among slowly progressing elderly chronic kidney disease patients referred to nephrology care: an observational study
- (2017) Ulrika Hahn Lundström et al. BMC Nephrology
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Response by Peralta et al to Letter Regarding Article, “Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial”
- (2016) Carmen A. Peralta et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question
- (2015) Mario Pacilio et al. JOURNAL OF NEPHROLOGY
- Diabetic nephropathy: landmark clinical trials and tribulations
- (2015) Gary C.W. Chan et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Influence of Dietary Protein on Glomerular Filtration Before and After Bariatric Surgery: A Cohort Study
- (2014) Allon N. Friedman et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes
- (2013) E. Jennifer Weil et al. DIABETES
- Outcomes of Early versus Late Nephrology Referral in Chronic Kidney Disease: A Systematic Review
- (2011) Neil A. Smart et al. AMERICAN JOURNAL OF MEDICINE
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now